

11 April 2024

## Treatment of Dermatological Conditions

1. How many patients were treated in the last 4 months (December 2023 to March 2024) by the Dermatology Department with each of the following products:

Abrocitinib	6
Acitretin	15
Alitretinoin	15
Azathioprine	<5
Baricitinib	<5
Ciclosporin	<5
Dupilumab	164
Lebrikizumab	<5
Methotrexate	<5
Mycophenolate mofetil	<5
Pimecrolimus	<5
Phototherapy (UVB or PUVA)	<5
- for Atopic Dermatitis only	
Tacrolimus ointment	
Tralokinumab	<5
Upadacitinib	28

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. Of the patients treated in the last 4 months with any of the products listed in Question 1, please provide the number of patients by the following age group:

Age 6-11	17
Age 12-17	29
Age 18 and above	319